Company research
EXOZYMES INC.
CIK 2010788Updated Nov 10, 2026
SecurityEXOZ · NASDAQ · equity
Historical securities (1)
IZTC · OTC · equity · closed Feb 11, 2025Name history
Invizyne Technologies Inc · through Jan 21, 2025
EXOZ price & chart
Loading TradingView…
NASDAQ:EXOZ on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery ↗
eXoZymes prices $5.33M public offering of stock and warrants ↗
SEC disclosures
EXOZYMES INC. files definitive proxy statement ↗
Recent filings
Show 5 more recent filings
Other Events
Items 8.01, 9.01
DEFA14A filing
DEF 14A filing
Other Events
Items 8.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 7,719,049Source | 3,560,365Source | 7,982,355Source | 9,676,909Source | — | 4,018,841Source | 11,525,692Source | — | 5,971,517Source | 13,034,404Source | 3,558,509Source |
| Property, Plant and Equipment, NetUSD | 763,012Source | 739,606Source | 670,908Source | 821,305Source | — | 747,858Source | 842,990Source | — | 764,401Source | 882,445Source | 753,376Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,098,687Source | 233,935Source | 5,652,696Source | 6,985,858Source | — | 1,444,562Source | 8,511,477Source | — | 3,039,343Source | 9,719,310Source | 66,533Source |
| Assets, CurrentUSD | 5,606,050Source | 1,422,591Source | 6,168,795Source | 7,531,030Source | — | 2,089,970Source | 9,418,847Source | — | 3,939,588Source | 10,820,382Source | 1,213,614Source |
| Prepaid Expense and Other Assets, CurrentUSD | 204,720Source | 634,693Source | 296,227Source | 287,419Source | — | 342,545Source | 312,210Source | — | 382,886Source | 363,790Source | 264,762Source |
| Operating Lease, Right-of-Use AssetUSD | 1,124,925Source | 1,398,168Source | 954,097Source | 1,194,981Source | — | 981,092Source | 1,263,855Source | — | 1,053,641Source | 1,331,577Source | 1,591,519Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 2,344,627Source | 7,161,683Source | 4,328,255Source | 2,441,204Source | — | 2,490,741Source | 2,644,061Source | — | 2,574,268Source | 2,613,629Source | 3,942,828Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 8Source | 6Source | 9Source | 8Source | — | 8Source | 8Source | — | 8Source | 8Source | 6Source |
| Additional Paid in CapitalUSD | 23,824,070Source | 6,508,660Source | 30,007,644Source | 23,398,362Source | — | 25,003,031Source | 22,684,002Source | — | 24,501,933Source | 22,366,725Source | 5,700,298Source |
| Retained Earnings (Accumulated Deficit)USD | -18,449,656Source | -10,109,984Source | -26,353,553Source | -16,162,665Source | — | -23,474,939Source | -13,802,379Source | — | -21,104,692Source | -11,945,958Source | -6,084,623Source |
| Stockholders' Equity Attributable to ParentUSD | 5,374,422Source | -3,601,318Source | 3,654,100Source | 7,235,705Source | -2,262,222Source | 1,528,100Source | 8,881,631Source | -1,249,967Source | 3,397,249Source | 10,420,775Source | -384,319Source |
| Liabilities and EquityUSD | 7,719,049Source | 3,560,365Source | 7,982,355Source | 9,676,909Source | — | 4,018,841Source | 11,525,692Source | — | 5,971,517Source | 13,034,404Source | 3,558,509Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 1,238,362Source | 5,802,300Source | 1,617,954Source | 1,216,943Source | — | 1,582,385Source | 1,444,309Source | — | 1,566,901Source | 1,333,245Source | 2,415,294Source |
| Operating Lease, Liability, CurrentUSD | 274,301Source | 223,761Source | 297,778Source | 243,691Source | — | 289,804Source | 236,795Source | — | 281,979Source | 230,027Source | 224,988Source |
| Accounts Payable, CurrentUSD | 904,353Source | 908,606Source | 1,274,226Source | 930,629Source | — | 1,234,080Source | 1,071,802Source | — | 1,235,337Source | 924,252Source | 702,911Source |
| Operating Lease, Liability, NoncurrentUSD | 926,587Source | 1,222,348Source | 700,287Source | 1,021,172Source | — | 777,150Source | 1,089,629Source | — | 852,575Source | 1,156,805Source | 1,386,831Source |
| Additional Financial Items | |||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 428,977Source | 481,750Source | 538,714Source |
| Additional Paid in Capital, Common Stock | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 501,098Source | 317,277Source | 1,988,105Source | 1,125,639Source | 281,538Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -214,496Source | -142,122Source | -219,923Source | -145,037Source | 72,787Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,524,441Source | -1,133,533Source | -6,502,040Source | -8,505,650Source | -1,180,870Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -57,604Source | -31,046Source | -150,218Source | -359,216Source | -311,167Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 57,604Source | 31,046Source | 169,917Source | 396,451Source | 288,712Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -12,736Source | -43,254Source | -27,709Source | 18,517,643Source | 1,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,594,781Source | -1,207,833Source | -6,679,967Source | 9,652,777Source | -492,037Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,098,687Source | 233,935Source | 5,652,696Source | 6,985,858Source | 1,444,562Source | 8,511,477Source | 3,039,343Source | 9,719,310Source | 66,533Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,981Source | — | 6,252Source | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 63,559Source |
| Additional Financial Items | |||||||||||
| AmortizationUSD | — | — | — | — | — | — | -11,992Source | -13,455Source | -52,913Source | -54,359Source | -51,840Source |
| DepreciationUSD | — | — | — | — | — | — | 74,147Source | 70,503Source | 287,961Source | 267,382Source | 196,937Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | -8Source | -200,000Source |
| General and Administrative ExpenseUSD | — | — | 1,305,446Source | 888,239Source | 1,515,732Source | 1,745,054Source | 1,265,966Source | 1,375,712Source | 6,009,480Source | 4,063,339Source | 1,338,811Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -105,205Source | — | 42,267Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,286,991Source | -1,656,373Source | -2,878,614Source | -2,360,286Source | -2,370,247Source | -1,856,421Source | -9,158,734Source | -5,861,335Source | -2,038,389Source |
| Operating Costs and ExpensesUSD | — | — | 2,522,208Source | 1,611,726Source | 2,953,890Source | 2,548,045Source | 2,386,974Source | 1,950,728Source | 9,716,471Source | 5,932,105Source | 1,866,291Source |
| Other Nonoperating Income (Expense)USD | — | — | 176,032Source | — | 102,362Source | 111,202Source | 3,011Source | — | 88,746Source | -6,834Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | 580,206Source | — | — | — | — | 14,528,964Source | — |
| Gain (Loss) on Sale of Derivatives | — | — | — | — | —Source | — | — | — | — | — | — |
| Operating Lease, Expense | — | — | — | — | — | — | —Source | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | 70,069Source |
| Operating Income (Loss)USD | — | — | -2,522,208Source | -1,611,726Source | -2,953,890Source | -2,548,045Source | -2,386,974Source | -1,950,728Source | -9,716,471Source | -5,932,105Source | -1,796,222Source |
| Other Nonoperating Income (Expense)USD | — | — | 176,032Source | — | 102,362Source | 111,202Source | 3,011Source | — | 88,746Source | -6,834Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,286,991Source | -1,656,373Source | -2,878,614Source | -2,360,286Source | -2,370,247Source | -1,856,421Source | -9,263,939Source | -5,861,335Source | -1,996,122Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -105,205Source | — | 42,267Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,286,991Source | -1,656,373Source | -2,878,614Source | -2,360,286Source | -2,370,247Source | -1,856,421Source | -9,158,734Source | -5,861,335Source | -2,038,389Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.27Source | -0.27Source | -0.33Source | -0.28Source | -0.28Source | -0.22Source | -1.09Source | -0.89Source | -0.33Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.27Source | -0.27Source | -0.33Source | -0.28Source | -0.28Source | -0.22Source | -1.09Source | -0.89Source | -0.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 8,387,250Source | 6,252,349Source | 8,660,246Source | 8,377,265Source | 8,458,847Source | 8,367,810Source | 8,381,444Source | 6,563,255Source | 6,250,002Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 8,387,250Source | 6,252,349Source | 8,660,246Source | 8,377,265Source | 8,458,847Source | 8,367,810Source | 8,381,444Source | 6,563,255Source | 6,250,002Source |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 1,305,446Source | 888,239Source | 1,515,732Source | 1,745,054Source | 1,265,966Source | 1,375,712Source | 6,009,480Source | 4,063,339Source | 1,338,811Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 59,185Source | -44,647Source | 1,840Source | 76,557Source | 13,716Source | 94,307Source | 363,786Source | 77,612Source | 100Source |
| Labor and Related ExpenseUSD | — | — | 845,174Source | 546,095Source | 1,127,667Source | 1,068,838Source | 830,724Source | 613,924Source | 3,635,756Source | 2,527,772Source | 596,174Source |
| Operating Costs and ExpensesUSD | — | — | 2,522,208Source | 1,611,726Source | 2,953,890Source | 2,548,045Source | 2,386,974Source | 1,950,728Source | 9,716,471Source | 5,932,105Source | 1,866,291Source |
| Other General and Administrative ExpenseUSD | — | — | 214,181Source | 56,940Source | 161,422Source | 265,449Source | 147,258Source | 204,236Source | 836,076Source | 329,660Source | 284,496Source |
| Research and Development ExpenseUSD | — | — | 1,216,762Source | 723,487Source | 1,438,158Source | 802,991Source | 1,121,008Source | 575,016Source | 3,706,991Source | 1,868,766Source | 527,480Source |
| Interest Expense | — | — | — | —Source | — | — | — | — | — | — | — |
| Operating Lease, Expense | — | — | — | — | — | — | —Source | —Source | — | — | — |
Offerings
Registration 333-299905
Registration 333-292781
Filing attachments
ex107.htm · S-1 · 2026-11-06
Calculation of Filing Fee Tables S-1 EXOZYMES INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Ag…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company’s ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes’ pipeline a…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 eXoZymes Inc. Announces Closing of $6 Million Public Offering Los Angeles, CA - June 17, 2026 - eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes” or “Company”), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants. The offering consisted of 330,575 units, including 34,440 units sol…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-08
EX-99.1 6 ex99-1.htm EX-99.1 Exhibit 99.1 eXoZymes, Inc. Announces Pricing of Public Offering of Common Stock and Warrants Los Angeles, CA -- June 8, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes” or “Company”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company h…
Read attachment ↗